Gilead Sciences, Inc. GILD

NASDAQ US Health Care Biotechnology

$168.04 ▼ -0.76% ($-1.28)

Index member: S&P 500

Open $169.75

Prev Close $169.32

Day Range $167.61 – $170.44

52W Range $116.88 – $176.58

Market Cap $207.72B

P/E (TTM) 24.60

Beta 0.38

Div Yield 3.98%

EPS (TTM) $-3.15

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1992-01-22
Shares Out.	1,240,340,000
Website	gilead.com ↗
Phone	13026587581
Employees	17,000
Revenue	$8.30B
Gross Profit	$6.73B
Net Income	$2.43B
Free Cash Flow	$13.78B
Total Assets	$51.41B
Total Liabilities	$38.45B
Equity	$12.96B

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences, Inc. is a publicly traded company under the ticker symbol GILD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.